Analyte | Mean methylation [%]/mRNA expression [n.c.]; [95% CI] | Correlation with mRNA expression | Correlation with lymphocyte score | Overall survival (Cox proportional hazards analysis) | |||
---|---|---|---|---|---|---|---|
Spearman’s ρ | P value | Spearman’s ρ | P value | Hazard ratio [95% CI] | P value | ||
TIM-3 mRNA | 412; [367–457] | NA | NA | 0.506 | < 0.001 | 0.88 [0.81–0.97] | 0.007 |
TIM-3 cg19110684 (1) | 50.1; [47.6–52.6] | − 0.408 | < 0.001 | − 0.272 | < 0.001 | 1.07 [0.93–1.25] | 0.35 |
TIM-3 cg19646897 (2) | 61.4; [59.5–63.2] | − 0.492 | < 0.001 | − 0.315 | < 0.001 | 1.20 [0.89–1.63] | 0.24 |
TIM-3 cg15371617 (3) | 13.2; [12.1–14.3] | − 0.189 | < 0.001 | − 0.118 | 0.033 | 1.04 [0.88–1.24] | 0.62 |
TIM-3 cg17484237 (4) | 19.7; [18.4–21.0] | − 0.114 | 0.013 | − 0.071 | 0.20 | 1.08 [0.91–1.27] | 0.37 |
TIM-3 cg19063654 (5) | 57.9; [55.7–60.2] | 0.263 | < 0.001 | 0.179 | 0.001 | 0.91 [0.75–1.10] | 0.35 |
TIM-3 cg18374914 (6) | 35.9;[33.4–36.6] | 0.633 | < 0.001 | 0.432 | < 0.001 | 0.87 [0.74–1.04] | 0.12 |
Galectin 9 mRNA | 1306;[1183-1429] | NA | NA | 0.352 | < 0.001 | 0.83 [0.75–0.93] | 0.001 |
LGALS9 cg19654781 (7) | 68.2; [67.5–69.0] | − 0.186 | < 0.001 | − 0.135 | 0.014 | 0.87 [0.35–2.18] | 0.77 |
LGALS9 cg10699049 (8) | 79.2; [78.4–80.0] | − 0.045 | 0.33 | − 0.128 | 0.020 | 0.80 [0.33–1.96] | 0.63 |
LGALS9 cg27625456 (9) | 17.4; [15.7–19.0] | − 0.404 | < 0.001 | − 0.034 | 0.54 | 1.02 [0.91–1.14] | 0.77 |
LGALS9 cg21157094 (10) | 22.3; [21.0–23.6] | − 0.371 | < 0.001 | −0.091 | 0.10 | 1.07 [0.92–1.24] | 0.41 |
LGALS9 cg23290146 (11) | 33.6; [32.2–35.0] | − 0.418 | < 0.001 | −0.188 | 0.001 | 1.23 [0.98–1.54] | 0.078 |
LGALS9 cg05105919 (12) | 50.8; [49.5–52.1] | − 0.670 | < 0.001 | − 0.351 | < 0.001 | 1.30 [0.93–1.81] | 0.12 |
LGALS9 cg03909504 (13) | 31.9; [30.7–33.0] | 0.135 | 0.003 | 0.196 | < 0.001 | 0.84 [0.66–1.06] | 0.14 |
LGALS9 cg06852032 (14) | 85.7; [84.8–86.6] | 0.146 | 0.001 | 0.014 | 0.80 | 1.32 [0.58–3.02] | 0.50 |